Table 3.

Dose adjustment for study antibiotics‡

	Meropenem	Piperacillin–tazobactam
A. All sites
CrCl >50 mL/min*	1 g q8h	4.5 g q6h
CrCl 26–50 mL/min*	1 g q12h	3.375 g q6h (only if CCT <40)
CrCl 10–25 mL/min*	0.5 g q12h	2.25 g q6h
CrCl <10 mL/min*	0.5 g q24h	2.25 g q6h
Haemodialysis	0.5 g q24h (+0.5 g AD)	2.25 g q8h (+0.75 g AD)
Peritoneal dialysis	0.5 g q24h	2.25 g q8h
Continuous renal replacement therapy	By flow rate based on recommendations in https://doi.org/10.3389/fphar.2020.00786
B. In Canadian sites†
CrCl >40 mL/min		4.5 g q6hr
CrCl 20–40 mL/min		4.5 g q8hr
CrCl 10–20 mL/min		2.25 g q6hr
CrCl <10 mL/min		2.25 g q6hr
Haemodialysis		2.25 g q8hr (+0.75 g AD)
Peritoneal dialysis		2.25 g q8hr
Continuous renal replacement therapy		As above, by flow rate

*CrCl should be expressed in mL/min/1.73 m², using the modification of diet in renal disease formula, Cockroft and Gault equation or other means.

†In Canada, to conform with the existing product monograph and accounting for the unavailability of the 3.375 g dosage form in most hospitals, the following piperacillin–tazobactam dosing strategy will be used (as extended infusion of 3 hours).

‡CrCl - creatinine clearance; q - every; hr - hour; AD - after dialysis